Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT)

Stuebig, Thomas and Langer, Christian and Engelhardt, Monika and Muegge, Lars-Olof and Bassermann, Florian and Schreder, Martin and Schaefer-Eckart, Kerstin and Blau, Igor Wolfgang and Wolleschak, Denise and Reichle, Albrecht and Metzler, Ivana and Metzner, Bernd and Rollig, Christoph and Hertenstein, Bernd and Duerk, Heinz and Biersack, Harald and Menzel, Helge and Dechow, Tobias and Schleicher, Jan and Gramatzki, Martin and Bruemmendorf, Tim H. and Fuhrmann, Stephan and Bittrich, Max and Appelt, Franziska and Mueller, Martina and Kroenke, Jan and Reusch, Julia and Schmidt, Christian and Brueggemann, Monika and Held, Swantje and Knop, Stefan and Einsele, Hermann (2018) Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT). BLOOD, 132 (Suppl1): 1979. ISSN 0006-4971, 1528-0020

Full text not available from this repository.
Item Type: Article
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Depositing User: Petra Gürster
Date Deposited: 21 Apr 2020 08:10
Last Modified: 21 Apr 2020 08:10
URI: https://pred.uni-regensburg.de/id/eprint/13506

Actions (login required)

View Item View Item
pred is powered by EPrints 3.4 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.